Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-cash Items: 2012-2024

Historic Non-cash Items for Capricor Therapeutics (CAPR) over the last 6 years, with Dec 2024 value amounting to $101.8 million.

  • Capricor Therapeutics' Non-cash Items rose 653.98% to $101.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $101.8 million, marking a year-over-year increase of 653.98%. This contributed to the annual value of $101.8 million for FY2024, which is 653.98% up from last year.
  • Capricor Therapeutics' Non-cash Items amounted to $101.8 million in Q4 2024, which was up 513.18% from $16.6 million recorded in Q3 2024.
  • In the past 5 years, Capricor Therapeutics' Non-cash Items ranged from a high of $101.8 million in Q4 2024 and a low of $171,000 during Q1 2020.
  • Its 3-year average for Non-cash Items is $21.9 million, with a median of $14.1 million in 2023.
  • In the last 5 years, Capricor Therapeutics' Non-cash Items slumped by 72.26% in 2020 and then surged by 4,870.76% in 2021.
  • Over the past 5 years, Capricor Therapeutics' Non-cash Items (Quarterly) stood at $4.2 million in 2020, then spiked by 81.74% to $7.7 million in 2021, then soared by 31.17% to $10.1 million in 2022, then surged by 33.66% to $13.5 million in 2023, then skyrocketed by 653.98% to $101.8 million in 2024.
  • Its Non-cash Items was $101.8 million in Q4 2024, compared to $16.6 million in Q3 2024 and $19.2 million in Q2 2024.